Biocryst Pharmaceuticals Inc (BCRX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biocryst Pharmaceuticals Inc (BCRX)

BCRX 6.860

-6.3%

Nov 3 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: IRWIN JAMES FRANKEL	1/24/2008 2:47:48 PM
	of 269

BCRX BioCryst Pharm: Not the season for Peramivir; many additional questions remain - Rodman & Renshaw (4.93 -0.36) Rodman & Renshaw notes that yesterday, BCRX announced updated results from the co's Phase 2 trial of IM peramivir in influenza infected patients. In today's conference call, they note the co elaborated that a statistically significant, dose-dependent reduction in influenza virus shedding was seen in both peramivir doses evaluated as compared to placebo. While the analysis appears encouraging, they say the fact that there is no correlation between viral load reduction and improvement in clinical symptoms suggests a higher dose may be required to improve the efficacy of the drug. Based on these results, they note BCRX has decided to forego moving into pivotal studies this year and plans to initiate another Phase 2 trial evaluating both 300 mg and a higher dose of peramivir using a new formulation. While they applaud the co's strategy to take the time to evaluate the various parameters that could impact the efficacy of the drug, they believe the stock could be weak in the near-term due to the delay in the development of peramivir.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next